Abstract:Background Despite PD-L1 (Programmed death receptor ligand-1) expression on tumor cells and cytotoxic T lymphocytes tumor infiltration in the tumor microenvironment, human pancreatic cancer stands out as one of the human cancers that does not respond to immune checkpoint inhibitor (ICI) immunotherapy. Epigenome dysregulation has emerged as a major mechanism in T cell exhaustion and non-response to ICI immunotherapy, we, therefore, aimed at testing the hypothesis that an epigenetic mechanism compensates PD-L1 function to render pancreatic cancer non-response to ICI immunotherapy. Methods Two orthotopic pancreatic tumor mouse models were used for chromatin immunoprecipitation-Seq and RNA-Seq to identify genome-wide dysregulation of H3K4me3 and gene expression. Human pancreatic tumor and serum were analyzed for osteopontin (OPN) protein level and for correlation with patient prognosis. OPN and PD-L1 cellular location were determined in the tumors using flow cytometry. The function of WDR5-H3K4me3 axis in OPN expression were determined by Western blotting. The function of H3K4me3-OPN axis in pancreatic cancer immune escape and response to ICI immunotherapy was determined in an orthotopic pancreatic tumor mouse model. Results Mouse pancreatic tumors have a genome-wide increase in H3K4me3 deposition as compared with normal pancreas. OPN and its receptor CD44 were identified being upregulated in pancreatic tumors by their promoter H3K4me3 deposition. OPN protein is increased in both tumor cells and tumor-infiltrating immune cells in human pancreatic carcinoma and is inversely correlated with pancreatic cancer patient survival. OPN is primarily expressed in tumor cells and monocytic myeloid-derived suppressor cells (M-MDSCs), whereas PD-L1 is expressed in tumor cells, M-MDSCs, polymorphonuclear MDSCs and tumor-associated macrophages. WDR5 is essential for H3K4me3-specific histone methyltransferase activity that regulates OPN expression in tumor cells and MDSCs. Inhibition of WDR5 significantly decreased OPN protein level. Inhibition of WDR5 or knocking out of OPN suppressed orthotopic mouse pancreatic tumor growth. Inhibition of WDR5 also significantly increased efficacy of anti-PD-1 immunotherapy in suppression of mouse pancreatic tumor growth in vivo. Conclusions OPN compensates PD-L1 function to promote pancreatic cancer immune escape. Pharmacological inhibition of the WDR5-H3K4me3 epigenetic axis is effective in suppressing pancreatic tumor immune escape and in improving efficacy of anti-PD-1 immunotherapy in pancreatic cancer.

Hypoxia‐driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial–mesenchymal transition and cancer stem cell‐like properties by modulating forkhead box protein M1

Osteopontin promotes a cancer stem cell-like phenotype in hepatocellular carcinoma cells via an integrin-NF-kappa B-HIF-1 alpha pathway

Over‐expression of FoxM1 Leads to Epithelial–mesenchymal Transition and Cancer Stem Cell Phenotype in Pancreatic Cancer Cells

Osteopontin Promotes Gastric Cancer Metastasis by Augmenting Cell Survival and Invasion Through Akt‐mediated HIF‐1α Up‐regulation and MMP9 Activation

Osteopontin Promotes Ovarian Cancer Progression and Cell Survival and Increases HIF‐1α Expression Through the PI3‐K/Akt Pathway

The Critical Roles of Activated Stellate Cells-Mediated Paracrine Signaling, Metabolism and Onco-Immunology in Pancreatic Ductal Adenocarcinoma

Osteopontin Induces Autophagy to Promote Chemo-Resistance in Human Hepatocellular Carcinoma Cells.

Osteopontin Promotes Hepatocellular Carcinoma Progression Through Inducing JAK2/STAT3/NOX1-mediated ROS Production

Osteopontin promotes gastric cancer metastasis by augmenting cell survival and invasion through Akt-mediated HIF-1alpha up-regulation and MMP9 activation

Hypoxia Promotes Pancreatic Cancer Cell Migration, Invasion, and Epithelial-Mesenchymal Transition Via Modulating the FOXO3a/DUSP6/ERK Axis.

Overexpression of FoxP 1 is a novel biomarker of malignant human pancreatic cancer

OSBPL10‐CNBP axis mediates hypoxia‐induced pancreatic cancer development

Osteopontin As a Multifaceted Driver of Bone Metastasis and Drug Resistance

Hypoxia promotes the metastasis of pancreatic cancer through regulating NOX4/KDM5A-mediated histone methylation modification changes in a HIF1A-independent manner

Osteopontin and its downstream carcinogenic molecules: regulatory mechanisms and prognostic value in cancer progression

WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape

Osteopontin Promotes the Progression of Gastric Cancer Through the NF-κB Pathway Regulated by the MAPK and PI3K

Abstract 2695: Osteopontin Regulated Epithelial-Mesenchymal Transition Via PI3K/AKT Signaling Pathway in Hepatocellular Carcinoma.

Osteopontin Induces Epithelial-to-Mesenchymal Transitions in Human Lung Cancer Cells Via PI3K/Akt and MEK/Erk1/2 Signaling Pathways

Osteopontin Promotes Metastasis of Intrahepatic Cholangiocarcinoma Through Recruiting MAPK1 and Mediating Ser675 Phosphorylation of Β-Catenin

C-C Chemokine Receptor Type 1 Mediates Osteopontin-Promoted Metastasis in Hepatocellular Carcinoma